OncoHost Launches PROphet® NSCLC Test in the United States
Original source here
Predictive blood test guides first-line treatment decisions for advanced unresectable non-small cell lung cancer patients
BINYAMINA, Israel, Feb. 1, 2023 /PRNewswire/ — OncoHost, a precision diagnostics company centered on predictive biomarker development for improved patient care, today announced the official launch of its PROphet® non-small lung cancer (NSCLC) Test in the United States.
OncoHost’s first test, PROphet® NSCLC, guides first-line treatment decisions for advanced unresectable non-small lung cancer patients.
The PROphet® NSCLC Test provides clinicians with actionable clinical insights into optimal first-line therapeutic choices and a better understanding of their patients’ personalized cancer dynamics. Requiring just one pre-treatment blood test, PROphet® scans approximately 7,000 proteins in a patient’s blood plasma and delivers a report that predicts their clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment plans.
“After years of research, development, and determination, we are proud to be launching our PROphet® NSCLC test in the United States,” said Dr. Ofer Sharon, CEO of OncoHost. “While driver mutation detection is essential in determining effective treatment, approximately 85% of all patients diagnosed with NSCLC do not have any detectable driver mutations. In these cases, the PROphet® NSCLC Test, when combined with PD-L1 results, will serve an invaluable purpose in predicting the best treatment plan for each individual patient. We hope to create a shift in the industry and improve the lives of those fighting this disease.”
The PROphet® algorithm is trained on OncoHost’s large-scale clinical trial, PROPHETIC. To date, the trial has over 1,500 patients recruited across 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field. The PROphet® NSCLC test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.
“We are thrilled to be launching the PROphet® NSCLC test, offering a predictive biomarker to guide treatment planning for this large subset of patients,” said Chris Dingman, OncoHost CCO. “Access to our test will have a significant impact on patient care and treatment protocols. The PROphet® Report will guide physicians’ treatment decisions by offering personalized insights on the predicted clinical benefit of immunotherapy. Combining these findings with the patients’ PD-L1 level will allow them to offer the most effective plan and avoid unnecessary treatments.”
To order the PROphet® NSCLC test, any physician can visit the OncoHost website at www.oncohost.com and complete a Test Requisition Form.
OncoHost is a precision diagnostics company headquartered in Binyamina, Israel, and Cary, centered on predictive biomarker development for improved patient care. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC Test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1500 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.
For more information, visit http://www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, and Facebook.